Business context and reporting period
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing DNA vaccines, immunotherapies and DNA-encoded monoclonal antibodies, delivered using its CELLECTRA devices. This Form 10-K reports the fiscal year ended December 31, 2020; quarterly figures are unaudited. The company had no approved products and no product-sale revenue. Its programs target COVID-19, HPV-related disease, cancers and other infectious diseases.
Financial performance and position
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $7.4 million | $4.1 million |
| Operating expenses | $131.5 million | $115.2 million |
| Loss from operations | $124.1 million | $111.1 million |
| Net loss attributable to Inovio | $166.4 million; $1.07 per share | $119.4 million; $1.21 per share |
| Cash used in operating activities | $178.0 million | $97.9 million |
- Revenue increased 80%, primarily from Advaccine and Plumbline; 68% came from Advaccine and 18% from Plumbline. Revenue remains collaboration- and milestone-based, not product sales. Inovio recorded $45.4 million of grant contributions as reductions to R&D expense, rather than revenue.
- R&D expense was $94.2 million, up 7%; general and administrative expense was $37.2 million, up 37%, including higher legal, communications and stock-based compensation costs. No product gross margin is reported because there are no commercial product sales.
- Year-end cash and cash equivalents were $250.7 million and short-term investments $160.9 million, totaling $411.6 million, versus $89.5 million a year earlier. Working capital was $429.5 million. Management said these resources were expected to fund planned requirements for at least 12 months from the financial-statement issuance date.
- Financing activities provided $465.3 million, principally from $454.5 million net ATM equity proceeds. Investing activities used $58.8 million, including investment purchases and maturities and $40.1 million proceeds from the GeneOne share sale.
- Debt carrying values at year-end were $14.1 million for convertible senior notes and $4.5 million for convertible bonds. Contractual debt payments, including interest and premiums, totaled approximately $25.9 million; operating lease commitments were $28.0 million.
- Year-end shares outstanding rose to 186.9 million from 101.4 million. A January 2021 stock offering generated a further $162.1 million net and issued 20.4 million shares; 207.6 million shares were outstanding on February 26, 2021.
Material changes and unusual items
- Despite higher revenue, operating loss widened 12% and operating cash use increased substantially. The net loss also included large non-operating and accounting items, so it does not reflect operating performance alone.
- A $75.7 million noncash charge from remeasuring the embedded derivative in the August 2019 convertible bonds was a major 2020 expense; the liability was derecognized when the bonds converted. Other notable items included a $36.6 million gain on investments in affiliated entities, a $4.1 million gain on Geneos deconsolidation, an $8.2 million bond-extinguishment loss and an $8.8 million gain on extinguishment of senior notes.
- During 2020, holders converted $62.1 million of senior-note principal into shares, and the August 2019 bonds converted in full. Inovio sold its GeneOne investment for $40.1 million and deconsolidated Geneos after losing control.
- For Q4 2020, revenue was $5.6 million and the loss attributable to Inovio was $24.3 million, compared with revenue of $0.3 million and a $37.7 million attributable loss in Q4 2019. Quarterly results were volatile, including a $19.2 million attributable profit in Q3 2020, driven by non-operating items.
Outlook, management commentary and key risks
- Inovio provided no quantitative revenue or earnings guidance. It expects substantial R&D spending and operating losses for the foreseeable future, and stated that additional capital will be needed to fund development over time.
- INO-4800’s planned U.S. Phase 3 development remained on partial FDA clinical hold over questions about the CELLECTRA 2000 delivery device. The company said it was working to address the FDA’s remaining questions; timing and approval to proceed were uncertain. The filing also cautions that an EUA or eventual product approval is not assured, while competing COVID-19 vaccines had already received regulatory authorization.
- After year-end, Inovio reported that VGX-3100 met the primary endpoint in the REVEAL 1 modified intention-to-treat population (23.7% versus 11.3%; p=0.022), but not in the intention-to-treat population (22.5% versus 11.1%; p=0.029, not statistically significant). Confirmatory REVEAL 2 enrollment was ongoing; these were post-year-end updates, not 2020 results.
- COVID-19-related restrictions delayed data collection in the VGX-3100 program and could disrupt trials, enrollment, manufacturing and collaboration work. Inovio also cited manufacturing-capacity and technology-transfer risks, including a dispute with former supplier VGXI. Prepaid manufacturing expenses were $35.7 million; the filing says deposits could be forfeited if manufacturing did not occur in 2021.
- Other material risks include dependence on a small number of licensees and government funding, competition, clinical and regulatory uncertainty, potential dilution or difficulty raising capital, and ongoing shareholder securities/derivative litigation and supplier-related litigation. Inovio reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions.
Most important facts for investors to verify
- Review the full audited statements and notes, especially the noncash derivative remeasurement, investment gains, debt-conversion accounting and cash-flow reconciliation.
- Track FDA correspondence and the status of the INO-4800 partial hold, device requirements, Phase 3 plans and any authorization applications.
- Assess the complete REVEAL 1 dataset, including the differing mITT and ITT findings, missing data, safety follow-up and REVEAL 2 results.
- Monitor cash burn, grant and contract receipts, manufacturing deposits and commitments, debt maturities, and the company’s stated need for future financing.
- Follow share-count changes and the status, potential costs and outcomes of the VGXI, GeneOne and shareholder litigation matters.